Phase 2 N=76 Pharmacogenetics of Doxazosin for Cocaine Dependence
Cocaine Dependence
Primary: Percentage of Cocaine Positive Urine Toxicology — 88.6; 85.6; 75.7; 75.9 percentage of positive urines
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=548 Staged Phase I/II Hepatitis C Prophylactic Vaccine
Hepatitis C
Primary: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months — 14; 14 Participants — p=0.317
Phase 2 N=11 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA) — 2.0 percent change
Phase 2 N=20 One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™
Metastatic Prostate Cancer
Primary: Number of Subjects With Adverse Events — 8; 9 Participants
Phase 2 N=180 A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
Ocular Discomfort
Primary: Change From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment. — -37.2; -35.7; -37.8; -37.3 score on a scale — p==0.974
Phase 2 N=20 A Study of Regorafenib in Advanced Pancreatic Cancer Patients
Pancreatic Cancer
Primary: Number of Patients Progression Free and Surviving at 16 Weeks as a Percent of All Enrolled Subjects — 2 Participants — p=0.824
Phase 2 N=406 An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number and Percentage of Subjects With American College of Rheumatology (ACR) 20 Response. — 224; 126; 350; 221 Participants
Phase 2 N=36 A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
Asymptomatic Hyperuricemia
Primary: Change From Baseline in Peak Urinary Excretion of Uric Acid (UA) on Day 7 — -12.87; -13.15 milligrams (mg)
Phase 2 N=189 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
Phase 2 N=87 Naltrexone for Individuals of East Asian Descent
Alcohol Use Disorder
Primary: Subjective Response - Craving for Alcohol — 1.7037; 1.9965; 2.1012; 1.8478 score on a scale — p=0.39
Phase 2 N=11 Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
Plasma Cell Myeloma
Primary: Proportion of Complete Response Plus Very Good Partial Response (VGPR) — 0 proportion of participants
Phase 2 N=121 Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Objective Response Rate (ORR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)…
Phase 2 N=16 Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
Pulmonary Cystic Fibrosis
Primary: Cohorts 1 and 2: Safety Assessments, Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]). — 0; 0; 0; 0 Participants
Phase 2 N=148 Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants — 27; 24 percentage of participants — p=0.4859
Phase 2 N=66 Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
Cystic Fibrosis
Primary: Clinically Significant Laboratory Abnormalities. — 1; 0; 8; 7 Participants